MarketPeel
Insider Trading Intelligence
SA

Samuel Agresta

OKUR
CHIEF MEDICAL OFFICER · ONKURE THERAPEUTICS, INC. · CIK 0001748961
FILING MIX · LIFETIME80%/20%
BUYS
8
SELLS
2
TOTAL VALUE
$3.73M
COMPANIES
2
ACTIVE SINCE
Jan 2021
HOLDINGS NOW
110,000
AVG SELL PX
$8.25
TRADE KIND
SHOWING 10 / 10
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Samuel Agresta, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%-20.11%+0.77%-20.88%-20.88%
14d1+100.00%-14.22%+2.59%-16.81%-16.81%
30d1+100.00%-27.67%+1.20%-28.87%-28.87%
60d1+100.00%-60.33%-0.47%-59.86%-59.86%
90d1+100.00%-56.00%+2.43%-58.43%-58.43%
180d1+100.00%-30.78%+14.82%-45.60%-45.60%
1y1+100.00%-31.11%+27.56%-58.67%-58.67%
2y1+100.00%-44.67%+49.81%-94.47%-94.47%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
OKUR · 110,000 shares · as of Apr 1, 2026
032,84965,69898,547131,39620252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 8 buys / 2 sellsCOVERAGE · 22 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
110,000110,000Apr 1, 2026Apr 3, 2026View →
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
45,00045,000Jan 27, 2025Jan 29, 2025View →
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
131,396131,396Oct 4, 2024Oct 8, 2024View →
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
18,58818,588Oct 4, 2024Oct 8, 2024View →
FHTX
FOGHORN THERAPEUTICS INC.
PURCHASE
Chief Medical Officer
311,297$3.72$1.16M311,297Aug 16, 2023Aug 18, 2023View →
FHTX
FOGHORN THERAPEUTICS INC.
SALE
Chief Medical Officer
311,297$8.25$2.57M0Aug 16, 2023Aug 18, 2023View →
FHTX
FOGHORN THERAPEUTICS INC.
SALE
Chief Medical Officer
311,2970Aug 16, 2023Aug 18, 2023View →
FHTX
FOGHORN THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
60,00060,000Jan 26, 2023Jan 30, 2023View →
FHTX
FOGHORN THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
125,000125,000Jan 26, 2022Jan 28, 2022View →
FHTX
FOGHORN THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
100,000100,000Jan 28, 2021Feb 1, 2021View →
Other insiders · OKUR
Loading peer insiders…
About this filer
CIK 0001748961
ROLE
Chief Medical Officer
PRIMARY
OKUR
COMPANIES
2
ACTIVE SINCE
Jan 2021
MARKETPEEL · /INSIDER/0001748961DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback